Azathioprine in rheumatoid arthritis
- PMID: 4884653
- PMCID: PMC1981902
- DOI: 10.1136/bmj.1.5641.420
Azathioprine in rheumatoid arthritis
Abstract
The ability of azathioprine to reduce the corticosteroid requirements of patients with severe rheumatoid arthritis was tested under double-blind conditions against placebo. After 12 months a significant mean dose reduction of 36% was achieved without undue side-effects. This form of therapy promises to be an advance in the management of severe rheumatoid arthritis.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources